HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness
Seminars in Immunology · 2025
DOI: 10.1016/j.smim.2025.102004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunology, 2025. Verfasst von Shan He und 2 weiteren Autor:innen. Beteiligte Einrichtung: Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Immunotherapy, Adoptive, Hepatitis B virus. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Government of Singapore Ministry of Health.
Abstract (Originalsprache)
Hepatocellular carcinoma developing in patients with HBV chronic infection are marked by expression of whole or partial HBV antigens through a highly tissue-specific process, determined by the hepatotropism of HBV. HBV antigens are therefore a possible target for adoptive T cell immunotherapy as their expression and, consequently, potential on-target off-tumour events, are confined to the liver compartment with no involvement of other organs. Here we summarise the research steps to develop T cell therapy that utilises viral antigen as a tumour antigen in HBV-related HCC and discuss the efficacy and the potential mechanisms of action of HBV-specific T cell receptor (TCR)-redirected T cells in phase I clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
- Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Electronic address: antonio@duke-nus.edu.sg.
Förderung
- Government of Singapore Ministry of Health
Zitieren
APA
He, S., Tan, A. T., & Bertoletti, A. (2025). HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness. Seminars in Immunology. https://doi.org/10.1016/j.smim.2025.102004
Vancouver
He S, Tan AT, Bertoletti A. HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness. Seminars in Immunology. 2025. doi:10.1016/j.smim.2025.102004
BibTeX
@article{He2025,
author = {He, Shan and Tan, Anthony T and Bertoletti, Antonio},
title = {HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness},
journal = {Seminars in Immunology},
year = {2025},
doi = {10.1016/j.smim.2025.102004}
}
EUVIMED